Results Seventy-two per cent of patients had one or more symptoms directly attributable to the tumour. These included blurred vision
(36%), photopsia (22%), visual field loss (16%), floaters (4%) and metamorphopsia (4%). 36 patients (72%) had one or more symptoms, which included blurred vision (18), photopsia (11), visual field loss (8), floaters (2) and metamorphopsia (2) . Fourteen patients (28%) were asymptomatic and presented during the course of a routine eye test. Twenty-one patients (42%) were identified as having experienced avoidable delays in the diagnosis of their uveal melanoma. These included 6 patients seen by an optometrist and 3 patients seen by a general practitioner, who had their tumour missed or misdiagnosed. One patient experienced a delay of 6 months due to his referral letter being mislaid. Four patients had their tumour misdiagnosed as naevus or macular degeneration by an ophthalmologist. In 3 patients diagnosed as having a suspicious naevus, no follow-up was arranged and in a further 3 patients no treatment was offered after a diagnosis of melanoma was made. One patient had his choroidal melanoma missed during a 3 year period whilst under follow-up for an epiretinal membrane. The patients were treated by ruthenium plaque radiotherapy (17), proton beam radiotherapy (9), trans scleral local resection (8) and enucleation (16). Patients who had experienced difficulties in detection or diagnosis were treated after a mean period of 6.6 months after first presentation (range 3.1 months to 5.2 years), compared with 4.2 weeks (range 10.0 days to 5.1 months)
for those who had experienced no difficulties (p = 0.003, Mann-Whitney U-test). Such patients were also more likely to need enucleation as opposed to radiotherapy or trans-scleral local resection. Eleven of 21 patients who had experienced delays in diagnosis underwent enucleation, compared with only 5 of 29 patients who had their tumours diagnosed promptly (p = 0.008, chi squared test) ( Table 1 ). The reasons for enucleation were: tumour diameter greater than 15 mm (4), involvement of more than a third of the ciliary body or angle (5) and optic disc involvement (7).
Discussion
The primary aim of treatment of uveal melanoma is to reduce the risk of death from metastases. However, up to half of patients treated for uveal melanoma eventually succumb to the disease. Whilst some authors believe that prompt treatment is essential to improve the chances of survival, S others have suggested that surgical manipulation may actually promote the dissemination of tumour cells. 9 Moreover, many patients may have already developed micrometastases at the time of treatment. Whether early treatment actually improves survival therefore remains highly controversial. A secondary aim of treatment is to conserve the eye with as much vision as possible, in terms of both visual acuity and visual field. Despite the small sample size, a significant finding of this study is that patients experiencing difficulties in detection or diagnosis were more likely to be treated by enucleation than by radiotherapy or trans-scleral local resection. It is likely that patients who have initially been reassured about their symptoms and discharged eventually present a later stage in the disease when the tumour has grown considerably in size or has invaded the angle or optic disc. Such tumours are often less amenable to an eye conserving treatment.
This study also identifies the main reasons for delay as failure to detect the tumour during ophthalmoscopy, misdiagnosis as naevus or macular degeneration and failure to follow-up a suspicious naevus. The policy of simply observing melanomas is hazardous and carries the risk of the patient developing an acutely painful eye that necessitates enucleation, as was seen in 3 patients in this study. The importance of lifelong follow-up of the suspicious naevus is also illustrated. We recorded 3 patients, discharged after a diagnosis of naevus, who returned several years later with large melanomas, two of which needed enucleation.
